InterVenn Biosciences and Aranscia Expand Commercialization Partnership for GlycoKnow™ Ovarian Cancer Diagnostic Test June 30, 2026
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test January 7, 2026
DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects October 16, 2025